Welcome to SJGLE.com! |Register for free|log in
Welcome to SJGLE.com! |Register for free|log in
Related Searches: Tea Vitamin Nutrients Ingredients paper cup packing
2023-06-02 Food Safety News
Tag: 2023 recalls
Data from the first quarter of 2023 shows that the number of food recalls in the U.S. were not that far off from other recalled products tracked by Sedgwick brand protection. Sedgwick’s recall index report for the 1st Quarter shows an increase of 14.2 percent.
It analyzes recall data from five key industries and marked the highest single-quarter total in four years.
As for food recalls, U.S. Food and Drug Administration recalls increased by 23.2 percent from the previous quarter to 117 events, while the number of units impacted decreased by 78.7 percent to 39.3 million.
The number of U.S. Department of Agriculture recalls held steady at 11 events for the second consecutive quarter, even as the number of pounds recalled increased 1,129 percent to 2.9 million.
Released quarterly, Sedgwick’s recall index report offers an in-depth analysis of the latest product recall data, safety regulations, and key challenges for the automotive, consumer products, food and beverage, medical device, and pharmaceutical industries.
It includes analysis and perspective from Sedgwick’s brand protection experts and network of strategic partners, the index is a key aid in helping mitigate recall risk, litigation, and reputational damage caused by product crises and in-market events.
Sedgwick reports that after a second consecutive record-breaking year for the number of units recalled in 2022, stakeholders have been watching closely to see whether that trend would continue into 2023.
However, data from the first quarter of 2023 reveals that the total number of recalled units — including non-food items — fell 21.6 percent from the previous quarter and lags far behind the number that had been recalled by this time in 2022. With three quarters in the year yet to be reported and regulatory and consumer scrutiny continuing to increase, there is still the possibility of a third consecutive year with over 1 billion recalled units.
Non-Food Highlights from Q1 2023 product recall data
Sedgwick Projections for the remainder of 2023
Further into 2023, technology advancements and increased adoption of electric vehicles (EVs) are expected to push regulators to move quickly to ensure that vehicles equipped with the latest features are safe for the road. Following in the footsteps of the European unio, we may also see a continued push from the Biden administration, regulators and legislators to adopt new standards for low to zero-emissions vehicles. Manufacturers should be prepared for a slate of new regulations and guidance as regulators work to ensure vehicle safety.
The U.S. consumer product industry will see strict regulatory enforcement continue from both the Consumer Product Safety Commission (CPSC) and the Federal Trade Commission (FTC). The CPSC will likely continue its more public efforts to pursue remedies from manufacturers and its practice of issuing civil penalties. Manufacturers will want to updat their recall and communications plans to align with CPSC’s new, more aggressive enforcement strategy.
The FDA has outlined an ambitious list of topics it will tackle in 2023 with a draft or final guidance, including allergens, dietary supplements, food additives, topics related to the Food Safety Modernization Act (FSMA), and labeling. The infant formula industry is also on notice from the FDA, which issued a constituent updat and sent a letter to stakeholders encouraging them to quickly improve their processes and implement the programs it outlined.
For the medical device industry, the FDA is focused on improving the supply chain and preventing shortages with a higher allocation for related programs in its draft budget for FY2024. The FDA is also testing two pilot programs that implement digital solutions for new product submissions and enhance stakeholder communications. As we continue through the year, cybersecurity and protecting patients from cyber threats and their consequences will be top of mind for the FDA and device manufacturers.
With the COVID-19 public health emergency now officially ended, pharmaceutical companies will need to be mindful of changes in drug distribution, clinical trials, and oversight that were granted during the pandemic. Cannabis and tobacco products will be another main focus for the FDA, which has begun research on the medical uses of cannabidiol and proposed tighter regulations around the manufacture of tobacco products.
“As the number of recall events increase across industries, the risks to manufacturers grow more serious, with increased regulatory enforcement and a more publicized recall process,” said Chris Harvey, Sedgwick senior vice president of brand protection. “Regulators are working to prioritize product safety while balancing innovation with oversight — meaning manufacturers can expect to contend with new rules and regulations. Businesses will need to remain agile to keep pace with these changes and prepare for future ones.”
about Sedgwick
Sedgwick, with 31,000 people in 80 countries, is a leading global provider of technology-enabled risk, benefits, and integrated business solutions. It provides a broad range of resources tailored to client’s specific needs in casualty, property, marine, benefits, brand protection, and other lines.
E-newsletter
Tags
Most Viewed
Latest News
Recommended Products